Results 131 to 140 of about 268,329 (333)

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami   +10 more
wiley   +1 more source

Sinicization of the Hospital for Special Surgery Lumbar Spine Surgery Expectations Survey and its reliability and validity test

open access: yesHuli yanjiu
ObjectiveTo translate the Hospital for Special Surgery Lumbar Spine Surgery Expectations Survey(HSS⁃LSSES) into Chinese version and test its reliability and validity.MethodsThe Brislin translation model was adopted for translation,back⁃translate,cross ...
HUANG Jiyun   +3 more
doaj  

Novel application of gamification to support undergraduate anatomy: Student perceptions and performance

open access: yesAnatomical Sciences Education, EarlyView.
Abstract Anatomy is a foundational component of various medical and paramedical disciplines. Existing research has suggested that games or game elements can improve student interest in musculoskeletal (MSK) anatomy. This project builds on previous gamification and serious game work and incorporates new anatomy‐based games into undergraduate anatomy ...
Emmeline Berger   +2 more
wiley   +1 more source

Reply to “Extending the Interpretation of Biomarker Dynamics in SOD1‐ALS Proteomics”

open access: yes
Annals of Neurology, EarlyView.
Christina Steffke   +2 more
wiley   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić   +4 more
wiley   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy